Cell line · CVCL_1059
Papers63
1 to 20 of 63
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Nuclear IDH3A Drives Transcriptional Programs in Melanoma via the YBX1-JUN/FOS Axis. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Gestodene Accelerates Cutaneous Wound Healing via PAR1-Selective Positive Allosteric Modulation. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| BGN/MDK Axis in the Melanoma Tumor Microenvironment Strengthens Tumor Malignancy by Modulating Cancer Cells and Cancer-Associated Fibroblasts Crosstalk. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An antibody-drug conjugate designed through clone and isotype selection restricts the growth of CSPG4-expressing triple-negative breast cancer. | NPJ Precis Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dysregulation of the PATZ1/CTCF Balance Silences ZBTB20 to Drive Melanoma Progression. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Synthesis of Benzopyrans and Quinolines with Nitrogenated Chain and Their Cytotoxicity Against Human Cancer Cell Lines. | ChemMedChem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Thrombomodulin facilitates melanoma progression via FAK- and ezrin-mediated phenotypic plasticity. | J Biomed Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the tumor cell-intrinsic ITGB2 axis inhibits melanoma progression. | Mol Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| RHOJ enhances adhesion and proliferation capabilities and suppresses apoptosis of melanoma cells by activating the Rap1 signaling pathway. | Transl Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| ZNF224 enhances the oncogenic function of p21 via p53 and AKT pathways in melanoma. | FEBS J | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| LPA suppresses HLA-DR expression in human melanoma cells: a potential immune escape mechanism involving LPAR1 and DR6-mediated release of IL-10. | Acta Pharmacol Sin | 2025 | Its Methods give the RRID and name the line | PubMed | |
| High-resolution profile of neoantigen-specific TCR activation links moderate stimulation to increased resilience of engineered TCR-T cells. | Nat Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Neddylation signaling inactivation by tetracaine hydrochloride suppresses cell proliferation and alleviates vemurafenib-resistance of melanoma. | Cell Biol Toxicol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Sex-dependent effects in the aged melanoma tumor microenvironment influence invasion and resistance to targeted therapy. | Cell | 2024 | Its Methods give the RRID and name the line | PubMed | |
| NRAS Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma Tumor Growth. | Mol Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the Melanocortin 1 Receptor in Melanoma: Biological Activity of α-MSH-Peptide Conjugates. | Int J Mol Sci | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Bioinformatics-based analysis reveals elevated CYTL1 as a potential therapeutic target for BRAF-mutated melanoma. | Front Cell Dev Biol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody-Drug Conjugate for Targeting Melanoma. | Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1059/papers